METTL1-mediated m7G hypomethylation promotes tsRNA biogenesis in prostate cancer [108], and m7G-modified tsRNA-LysTTT catalyzed by METTL1 enhances bladder cancer malignancy [109]. Here, METTL1 is linked to urinary bladder cancer.